In the Media

Lentigen Technology Inc., a Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma, Inc.

Posted on: Thursday, July 20th, 2017 @ 8:00 am

Lentigen Technology Inc., a leading provider of GMP lentiviral vectors, will further advance Living Pharma’s personalized chimeric antigen receptor (CAR) T-cell therapies targeting various cancers Co-founded by an award-winning University of Maryland, Baltimore (UMB), immunotherapy researcher, Living Pharma is the first UMB New Ventures Initiative start-up to execute a successful exit GAITHERSBURG, Md. and BALTIMORE, …

Living Pharma Adds Noted Oncologist to its Advisory Board

Posted on: Tuesday, November 1st, 2016 @ 3:32 pm

Baltimore, MD, November 1, 2016 – Living Pharma, Inc. announced today that it has added Aaron P. Rapoport, MD, to its advisory board. Dr. Rapoport is a professor in the Department of Medicine, the Gary Jobson Professor of Medical Oncology and the Director of the Blood and Marrow Stem Cell Transplant Program in the Greenebaum …

Living Pharma Adds Venture Capital Executive to its Advisory Board

Posted on: Wednesday, June 1st, 2016 @ 1:47 pm

Baltimore, MD, June 1, 2016 – Living Pharma, Inc. announced today that it has added Isai Peimer, PhD, to its advisory board.  Dr. Peimer is the former Managing Director of MedImmune Ventures, Inc., AstraZeneca’s investment fund, where he served from 2010 to 2016. Previously, he worked as a venture capitalist at Visium Asset Management, and as …

Living Pharma Signs Exclusive License Agreement with UMB for a Novel Universal CAR T Cell Platform Technology

Posted on: Thursday, January 28th, 2016 @ 1:56 pm

Baltimore, MD, January 28, 2016 – Living Pharma, Inc. announced today that it has entered into an exclusive license agreement with the University of Maryland, Baltimore (UMB) to develop Anti-Tag Chimeric Antigen Receptor (AT-CAR™) engineered T cell therapy. AT-CAR is a universal CAR T cell technology that enables the personalization of CAR T cell therapy to the …